Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase

Dupilumab is a dual inhibitor of interleukin-4 and interleukin-13 and is mainly used to treat moderate-to-severe atopic dermatitis. Post-marketing safety data related to dupilumab have been accumulated, and it has been found that ocular surface diseases are closely associated with dupilumab treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sunny, Lee, Jung Hyun, Park, Ji Hyun, Park, So Hyang, Park, Song Yi, Jung, Yong Woo, Choi, Soo An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275737/
https://www.ncbi.nlm.nih.gov/pubmed/34253801
http://dx.doi.org/10.1038/s41598-021-93750-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275737/
https://www.ncbi.nlm.nih.gov/pubmed/34253801
http://dx.doi.org/10.1038/s41598-021-93750-3

Ejemplares similares